Head to head
Senolytic CAR T cells against Senolytic vaccine (anti-GPNMB)
Two immune approaches to clearing senescent cells, engineered T cells against a vaccine. Every result for both is in mice, and no human trial of either for ageing or senescence is registered anywhere.
Column A
Senolytic CAR T cellsSenolytic chimeric antigen receptor T cells directed at uPAR
Living T cells engineered to recognise and kill senescent cells by a surface marker, uPAR. Every result is in mice, and no human trial of senolytic CAR T for ageing or senescence is registered anywhere.
Column B
Senolytic vaccine (anti-GPNMB)Senolytic vaccination against glycoprotein nonmetastatic melanoma protein B (GPNMB)
A vaccine that teaches the immune system to attack GPNMB, a protein enriched on senescent cells. In mice it removed GPNMB-positive cells and extended lifespan in male progeroid animals. There is no human trial.
Side by side, on the facts we can check
| Attribute | Senolytic CAR T cells | Senolytic vaccine (anti-GPNMB) |
|---|---|---|
| Category | Immune | Immune |
| FDA status | No senolytic CAR T product is approved, and none is in a registered human trial for ageing or senescence. CAR T therapy as a class is approved in the United States for certain blood cancers, which is a different target, a different patient and a different risk calculation. | Not approved anywhere and not in any registered human trial. This is a mouse result published in the peer-reviewed literature, not a product. |
| Half-life | Not applicable in the usual sense. This is a living cell product that expands on meeting its target and persists, so exposure is governed by the survival of the engineered cells rather than by drug clearance. | Not applicable. A vaccine is dosed as a course and its effect depends on the immune response it raises, not on clearance of the injected material. |
| Molecular weight | Not reported | Not reported |
| Mechanism | uPAR, the product of the PLAUR gene, is a glycosylphosphatidylinositol-anchored cell-surface receptor that is broadly upregulated during senescence, which makes it usable as a seno-antigen. A chimeric antigen receptor is a synthetic protein spliced into a T cell so the T cell recognises that surface antigen directly, without needing normal antigen presentation, and kills what carries it. Because the killing is done by a living cell that proliferates on encountering its target, one administration can in principle keep working, which is the mechanistic difference from a small molecule that clears within hours. The same property is the risk: an immune cell tuned to a target that healthy tissue also expresses at lower levels does not stop when the senescent cells are gone. | GPNMB is a transmembrane glycoprotein enriched on senescent cells, which makes it a seno-antigen: a surface tag the adaptive immune system can be trained to recognise. Vaccination raises antibodies and cellular immunity against GPNMB, so GPNMB-bearing cells are cleared by the immune system rather than by a drug. The appeal over small-molecule senolytics is that the killing step reuses machinery the body already has, and immune memory could in principle keep clearing newly senescent cells for a long time after a single course. The complication, established by the same group, is that GPNMB is itself a survival factor maintaining lysosomal integrity in senescent cells, so the target is not an inert flag. |
| Human studies cited | 0 | 0 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Senolytic CAR T cells and Senolytic vaccine (anti-GPNMB)?
Senolytic CAR T cells: Living T cells engineered to recognise and kill senescent cells by a surface marker, uPAR. Every result is in mice, and no human trial of senolytic CAR T for ageing or senescence is registered anywhere. Senolytic vaccine (anti-GPNMB): A vaccine that teaches the immune system to attack GPNMB, a protein enriched on senescent cells. In mice it removed GPNMB-positive cells and extended lifespan in male progeroid animals. There is no human trial.
Which has stronger research evidence, Senolytic CAR T cells or Senolytic vaccine (anti-GPNMB)?
This database does not grade compounds. It counts what was run in people: 0 of the 3 studies cited on the Senolytic CAR T cells profile were human work, against 0 of 3 for Senolytic vaccine (anti-GPNMB). Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Senolytic CAR T cells and Senolytic vaccine (anti-GPNMB) FDA-approved?
Senolytic CAR T cells: No senolytic CAR T product is approved, and none is in a registered human trial for ageing or senescence. CAR T therapy as a class is approved in the United States for certain blood cancers, which is a different target, a different patient and a different risk calculation.. Senolytic vaccine (anti-GPNMB): Not approved anywhere and not in any registered human trial. This is a mouse result published in the peer-reviewed literature, not a product..
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.